Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
Rdh12-KO Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

Rdh12-KO Mouse

Product Name
Rdh12-KO Mouse
Product ID
C001884
Strain Name
C57BL/6JCya-Rdh12em1/Cya
Backgroud
C57BL/6JCya
Status
Live Mouse
When using this mouse strain in a publication, please cite “Rdh12-KO Mouse (Catalog C001884) were purchased from Cyagen.”
Disease Animal Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Disease Animal Models

Basic Information

Validation Data

Related Resource

Basic Information
Gene Name
Rdh12
Gene Alias
--
NCBI ID
77974 (Mouse)
Chromosome
Chr 12 (Mouse)
MGI ID
MGI:1925224
Datasheet
Click here to download >>

Strain Description

Rdh12, also known as Retinol dehydrogenase 12, is an NADPH-dependent retinal reductase that is mainly expressed in the inner segments of photoreceptor cells. Rdh12 plays a crucial role in the visual cycle, which is a series of enzymatic reactions essential for the regeneration of visual pigments and is involved in the detoxification process of retinal aldehyde. Mutations in Rdh12 can lead to the degeneration of retinal photoreceptor cells, thereby affecting visual function. The mutations cause a decrease or loss of enzymatic activity in the retina, which in turn affects the progress of the visual cycle and hinders the regeneration of visual pigments. In addition, the mutations may also lead to the accumulation of retinal aldehyde, further damaging the retinal photoreceptor cells [1]. These factors act together, resulting in the degeneration of retinal photoreceptor cells and the loss of visual function. Mutations in Rdh12 are associated with Leber congenital amaurosis (LCA) and autosomal dominant retinitis pigmentosa (RP) [2].
The Rdh12-KO mouse is a knockout (KO) model in which exons 2-5 of the Rdh12 gene in mice are knocked out using gene-editing technology. This model can be used for the research on the pathogenic mechanisms of retinal diseases such as Leber congenital amaurosis (LCA) and autosomal dominant retinitis pigmentosa (RP) and the development of related treatment methods.
Reference
Fahim AT, Thompson DA. Natural History and Genotype-Phenotype Correlations in RDH12-Associated Retinal Degeneration. Adv Exp Med Biol. 2019;1185:209-213.
Jin J, Liang L, Jin K, Zhang HJ, Liu R, Shen Y. Associations Between Fundus Types and Clinical Manifestations in Patients with RDH12 Gene Mutations. Brain Topogr. 2022 Jul;35(4):525-535.

Strain Strategy

The mouse Rdh12 gene contains 7 exons. The ATG start codon is located in exon 1, and the TAG stop codon is located in exon 7. In this strain, the regions of exons 2-5 were knocked out using gene-editing technology.
Figure 1. Diagram of the gene editing strategy for the generation of Rdh12-KO mice.
Figure 1. Diagram of the gene editing strategy for the generation of Rdh12-KO mice.

Application Area

Research on Leber congenital amaurosis (LCA);
Research on autosomal dominant retinitis pigmentosa (RP).
Validation Data
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research